标题
Update on quinolone-containing rescue therapies for Helicobacter pylori infection
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 26, Issue 15, Pages 1733-1744
出版商
Baishideng Publishing Group Inc.
发表日期
2020-04-20
DOI
10.3748/wjg.v26.i15.1733
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition
- (2019) Mototsugu Kato et al. HELICOBACTER
- High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients
- (2019) Vignesh Shetty et al. Gut Pathogens
- Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018
- (2019) B. Bluemel et al. CLINICAL MICROBIOLOGY AND INFECTION
- Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study
- (2019) Ana Morilla Morilla et al. Gastroenterologia y Hepatologia
- 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy
- (2019) Hideki Mori et al. DIGESTION
- Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018
- (2019) Ju Yup Lee et al. HELICOBACTER
- Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia
- (2019) Alfizah Hanafiah et al. Infection and Drug Resistance
- Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study
- (2018) D.-S. Liu et al. CLINICAL MICROBIOLOGY AND INFECTION
- Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
- (2018) Wen Zhong Liu et al. HELICOBACTER
- Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori
- (2018) Soichiro Sue et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat
- (2017) Hidekazu Suzuki et al. JOURNAL OF GASTROENTEROLOGY
- Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens
- (2017) Hideki Mori et al. United European Gastroenterology Journal
- Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments ofHelicobacter pyloriinfection
- (2016) P.-Y. Chen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial
- (2016) Jyh-Ming Liou et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy
- (2016) Zhiqiang Song et al. DIGESTIVE AND LIVER DISEASE
- The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
- (2016) Carlo A. Fallone et al. GASTROENTEROLOGY
- Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study
- (2016) Kazunari Murakami et al. GUT
- Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report
- (2016) P Malfertheiner et al. GUT
- Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study
- (2016) Najat Bouihat et al. Microbial Drug Resistance
- Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014)
- (2016) Alba A. Trespalacios-Rangél et al. PLoS One
- Helicobacter pylorisecond-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments
- (2015) J. P. Gisbert et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection
- (2015) Seong tae Lee et al. Gut and Liver
- Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies forHelicobacter pyloriStrains Containing thegyrAMutation
- (2015) Hideki Mori et al. HELICOBACTER
- Helicobacter pylori gastritis—a novel distinct disease entity
- (2015) Hidekazu Suzuki et al. Nature Reviews Gastroenterology & Hepatology
- Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial
- (2015) Zhijun Cao et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Low efficacy of levofloxacin-doxycycline-based third-line triple therapy forHelicobacter pylorieradication in Italy
- (2015) Omero Alessandro Paoluzi WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy of 14-dvs7-d moxifloxacin-based triple regimens for second-lineHelicobacter pylorieradication
- (2015) Jae Jin Hwang WORLD JOURNAL OF GASTROENTEROLOGY
- Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure forHelicobacter pyloriinfection
- (2015) Ji Hyun Lim WORLD JOURNAL OF GASTROENTEROLOGY
- Comparative effectiveness and tolerance of treatments forHelicobacter pylori: systematic review and network meta-analysis
- (2015) Bao-Zhu Li et al. BMJ-British Medical Journal
- Comparative effectiveness and tolerance of treatments forHelicobacter pylori: systematic review and network meta-analysis
- (2015) Bao-Zhu Li et al. BMJ-British Medical Journal
- Comparison of Levofloxacin- and Moxifloxacin-Based Triple Therapies with Standard Treatment in Eradication of Helicobacter Pylori as First-Line Therapy
- (2015) Halil Rakici et al. DIGESTION
- The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea
- (2014) Kwang Hyun Chung et al. Gut and Liver
- Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
- (2014) Liam S. Redgrave et al. TRENDS IN MICROBIOLOGY
- Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea
- (2014) Kyu Keun Kang WORLD JOURNAL OF GASTROENTEROLOGY
- Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment ofHelicobacter pyloriInfection in Korea
- (2013) Ji Yoon Moon et al. Gut and Liver
- Efficacy of Two Levofloxacin-Containing Second-Line Therapies forHelicobacter pylori: A Pilot Study
- (2013) Turan Calhan et al. HELICOBACTER
- High secondary resistance to quinolones in German Helicobacter pylori clinical isolates
- (2013) Nicole Wueppenhorst et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan
- (2013) Kazunari Murakami et al. JOURNAL OF GASTROENTEROLOGY
- Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan
- (2013) Takahisa Furuta et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
- (2013) Wei-Chen Tai et al. Gastroenterology Research and Practice
- High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures
- (2012) K.-L. Goh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Randomized Comparison of Two Non-Bismuth-Containing Second-line Rescue Therapies for Helicobacter pylori
- (2012) Seng-Kee Chuah et al. HELICOBACTER
- Prevalence of Primary and Secondary Antimicrobial Resistance ofHelicobacter pyloriin Korea from 2003 through 2012
- (2012) Jung Won Lee et al. HELICOBACTER
- Fluoroquinolone Resistance in Helicobacter pylori: Role of Mutations at Position 87 and 91 of GyrA on the Level of Resistance and Identification of a Resistance Conferring Mutation in GyrB
- (2012) Emiko Rimbara et al. HELICOBACTER
- Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection
- (2012) Javier P. Gisbert et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Randomized Comparison of Two Nonbismuth-Containing Rescue Therapies for Helicobacter pylori
- (2011) Seng-Kee Chuah et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies
- (2011) Juntaro Matsuzaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of Helicobacter pylori Infection
- (2011) Stephan Miehlke et al. HELICOBACTER
- Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial
- (2011) J.-M. Liou et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance
- (2011) Jun-Won Chung et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Second-Line Levofloxacin-Based Triple Therapy's Efficiency for Helicobacter pylori Eradication in Patients With Peptic Ulcer
- (2011) Fatih Ermis et al. SOUTHERN MEDICAL JOURNAL
- Genotypic Resistance inHelicobacter pyloriStrains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies
- (2010) Jyh-Ming Liou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design
- (2010) J. M. Liou et al. GUT
- Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition
- (2010) Masahiro Asaka et al. HELICOBACTER
- Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy
- (2010) Juntaro Matsuzaki et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation
- (2009) H. Suzuki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations
- (2009) K. Murakami et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Moxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate
- (2009) Hyuk Yoon et al. HELICOBACTER
- Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial
- (2009) Josip Bago et al. WIENER KLINISCHE WOCHENSCHRIFT
- Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication
- (2008) S. Di Caro et al. DIGESTIVE AND LIVER DISEASE
- Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study of 300 Patients
- (2007) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More